Regulatory commentary and a community submission note that Hemostemix received favorable engagement from the FDA for its basket protocol strategy, according to a public post. The interaction suggests the agency is open to trial designs that test a single investigational product across multiple indications or patient subgroups within a unified framework. The communication, while brief, indicates potential regulatory flexibility for companies seeking streamlined, multi‑cohort development programs. Sponsors planning basket trials should still expect rigorous endpoint, statistical and safety oversight but may gain efficiencies in protocol activation and data harmonization. Clarification: a basket protocol tests one therapeutic across multiple diseases or molecular subtypes under a single master protocol to accelerate data collection and decision making. Sponsors must ensure robust subgroup powering and clear regulatory endpoints.